



*Just What Women
Want in Healthcare*

FOR IMMEDIATE RELEASE:

**AGILE THERAPEUTICS TO PRESENT AT
THE 10TH ANNUAL BIO CEO & INVESTOR CONFERENCE**

Princeton, NJ – February 5, 2008 – Agile Therapeutics, Inc., today announced that Thomas Rossi, Ph.D., President and Chief Executive Officer, will present at the *10th Annual BIO CEO & Investor Conference*, at the Waldorf-Astoria Hotel in New York City from February 11-13, 2008. Dr. Rossi will present a company overview, including a progress update for Agile's low-estrogen dose contraceptive patch currently in a Phase 2b multi-center, multi-cycle, dose-ranging ovulation suppression study.

Dr. Rossi's presentation will take place on February 13th at 11:45 AM in the Conrad Suite and he will be available for one-on-one meetings during the conference. For more information please visit <http://ceo.bio.org/opencms/ceo/2008/index.jsp>

About Agile Therapeutics, Inc.

Agile Therapeutics is a privately held, specialty pharmaceutical company focused on the development of innovative women's healthcare products. Historically, the women's healthcare market has been largely underserved by the pharmaceutical industry and thus offers unique opportunities to a company with proven expertise in clinical development, regulatory affairs, transdermal drug delivery and commercialization experience in this market segment. Agile's lead product is a Phase 2b, low-estrogen dose transdermal contraceptive patch. In a market research survey (Agile 2007) of 500 current contraceptive users, 65 percent of women confirmed their interest in trying a low-estrogen dose contraceptive patch. The company's low-estrogen dose patch offers a convenient, weekly form of birth control that is appealing to many women over taking a pill daily. Transdermal contraception has been shown to significantly enhance compliance by eliminating the need to remember daily doses of oral contraceptives.

Agile's current venture investors include ProQuest, the Hillman Company, TL Ventures and PA Early Stage Partners. The company has raised a total of \$30 million in venture funding to date. For more information please visit www.agiletherapeutics.com

#

Contact:
Tim Allison
LaVoie Group
978-745-4200 x 102
tallison@lavoiegroup.com